SYK · Q3 2025 Earnings
BullishStryker Corporation
Reported October 30, 2025
30-second summary
Stryker grew Q3 FY2025 revenue 10.3% to $6.06B with organic growth of 9.5%, and raised FY2025 guidance for the second consecutive quarter — organic sales to 9.8–10.2% and adjusted EPS to $13.50–$13.60. MedSurg & Neurotechnology (+14.4% reported, +8.4% organic) carried the print again, with Vascular +59.6% on continued Inari contribution, while Orthopaedics decelerated to +3.9% reported but delivered +12.5% ex-divested-Spinal (reported) and +11.4% organic. The quietly notable signal: the previously-quantified $175M tariff headwind was replaced this quarter with a ~$200M in-period estimate paired with a "slightly positive" FX-dependent comment on FY framing — a meaningful shift in how tariffs are being communicated.
Headline numbers
EPS
Q3 FY2025
$3.19
Revenue
Q3 FY2025
$6.06B
+10.3% YoY
Gross margin
Q3 FY2025
63.6%
Operating margin
Q3 FY2025
18.7%
Key financials
Q3 FY2025| Metric | Q3 FY2025 | YoY | Q2 FY2025 | QoQ |
|---|---|---|---|---|
| Revenue | $6.06B | +10.3% | $6.02B | +0.6% |
| EPS | $3.19 | — | $3.13 | +1.9% |
| Gross margin | 63.6% | — | 63.8% | -20bps |
| Operating margin | 18.7% | — | 18.5% | +20bps |
Guidance
Stryker raised FY2025 organic growth and EPS guidance; tariff quantification withdrawn but offset by rates commentary.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
Changes to prior guidance
| Metric | Period | Prior guide | New guide | Δ | Result |
|---|---|---|---|---|---|
| Organic net sales growth | FY2025 | 9.5% to 10.0% | 9.8% to 10.2% | midpoint +0.3pts (9.75% → 10.0%) | Raised |
| Adjusted net earnings per diluted share | FY2025 | $13.40 to $13.60 | $13.50 to $13.60 | low-end +$0.10 | Raised |
| Tariff impact | FY2025 | approximately $175 million | Withdrawn — no replacement | — | Withdrawn |
Segment KPIs
Q3 FY2025| Segment | Q3 FY2025 | YoY |
|---|---|---|
| MedSurg and Neurotechnology | $3.803B | +14.4% |
| Orthopaedics | $2.254B | +3.9% |
| Instruments | $0.76B | +11.9% |
| Endoscopy | $0.896B | +7.0% |
| Vascular | $0.525B | +59.6% |
| Neuro Cranial | $0.637B | +17.6% |
| MedSurg and Neurotechnology Organic Growth | 8.4% | — |
| Orthopaedics Organic Growth (excl. Spinal) | 12.5% | — |
Other KPIs
Q3 FY2025| Segment | Q3 FY2025 | YoY |
|---|---|---|
| United States | $4.571B | +11.4% |
| International | $1.486B | +6.9% |
| Adjusted Operating Income Margin | 25.6% | — |
| Adjusted Gross Profit Margin | 65.0% | — |
| Organic Net Sales Growth | 9.5% | — |
| Adjusted EPS Growth | 11.1% | — |
Management tone
Narrative arc: Q2 FY2025 (guidance raise on tariff relief) → Q3 FY2025 (second raise; tariff burden actually higher in-period, EPS resilience strengthens the case).
Margin expansion language hardened from commitment to declaration. Last quarter management framed +100bps of FY adjusted operating margin expansion as a target to be delivered; this quarter the framing is "We are firmly on track to deliver a second consecutive year of 100 basis points of adjusted operating margin expansion, backed by strong execution and conviction in the sustained growth and earnings power of our businesses." The words "firmly on track" and "conviction" are unusually direct for a medical-device print — management is no longer hedging on whether they hit it, only on whether they overshoot.
Tariff posture: in-period burden grew, FY framing turned conditional. Preston quantified the FY tariff impact at ~$200M this quarter, $25M above the prior $175M figure, and noted Q3 tariffs "picked up meaningfully versus Q2." Separately, on the FY outlook, FX is expected to have "a slightly positive impact on both sales and adjusted net earnings per diluted share should rates hold near current levels." The combination — bigger tariff hit absorbed, EPS still raised — is the operational signal worth holding onto.
Inari integration moved from on-track-with-caveats to on-track-clean. Last quarter acknowledged destocking, sales-rep churn, and quarterly-incentive removal as live issues; this quarter the language is "Inari remains on track to deliver double digit pro forma sales growth in 2025" with double-digit pro forma growth already delivered in Q3 FY2025. Destocking is expected to fully burn through by end of Q1 FY2026, after which teens-level procedural growth should translate cleanly.
EPS resilience reframed despite intensifying tariffs. Q3 FY2025 absorbed a higher tariff burden ($200M FY estimate vs. $175M prior guide; in-period tariffs "picked up meaningfully versus Q2") yet still delivered "double-digit adjusted EPS growth of 11.1% despite tariff headwinds" — and management raised the FY EPS low end. The tariff line got harder, not easier, and the structural-margin case strengthens accordingly.
Capital equipment and backlog framing moved from execution to visibility. "We exited Q3 with an elevated backlog...we expect continued strength in our order book" converts last quarter's healthy-demand commentary into a forward-visibility statement. This is the cleanest signal underpinning the guidance raise: backlog conviction, not just trailing strength.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Robbie Marcus · JP Morgan
Walk through global procedure volumes, market health, and capital equipment puts and takes, particularly on ortho strength versus medical softness.
Procedure volumes very healthy globally; capital markets strong with hospitals cash-purchasing Mako systems rather than leasing; communications has healthy order book with timing delays; medical experiences quarterly variability but tracking to strong full-year double-digit growth despite supply chain disruptions in emergency care.
Larry Beagleson · Wells Fargo
How to maintain 10% organic growth momentum in 2025; how to expand margins with increasing tariff headwinds; status of M&A strategy.
Fourth consecutive year of ~10% organic growth is sustainable and durable; more details at upcoming investor day; no change to M&A strategy; all businesses identifying targets in known adjacencies; peripheral was example from Q1 2024; strong balance sheet enables larger deals if value-creating; acquisitions are top capital allocation priority.
Ryan Zimmerman · BTIG
Assess orthopedics market health and Stryker's position to capitalize on competitor disruption; comment on price pressure seen in Q3.
Knee business in excellent position due to cementless leadership and Mako adoption; additional software improvements and new product innovations coming; price pressure reflects anniversarying of historical price improvements from years prior; orthopedics pricing still above historic levels; continuing to develop pricing discipline for future improvement.
Travis Steed · Bank of America
Detail Inari integration progress, sales force status, whether Q3 was low point, and forecast for double-digit growth; comment on STORE and PE trial data.
New Stryker sales leader in place; rapid hiring underway to offset Q2 churn; Q3 strong performance; Q3 not characterized as low point; expect double-digit growth Q4 and Q1; still burning through stocking through end of Q1; expect to reach mid-teens growth in procedures translating to double-digit revenue; very strong Q4 and Q1 expected; trajectory accelerates significantly post-Q1 once stocking headwind clears.
Philip Chickering · Deutsche Bank
Assess whether Q3 ortho growth reflects core market share gains or pull-forward demand driven by healthcare policy uncertainties.
Management characterizes growth as core growth driven by market share gains and organic market growth, not pull-forward; sees continued strong demand in Q4; osteoarthritis pain management is primary driver rather than policy concerns; no surgeon anxiety about procedure volume decline detected; market share gains evident as Stryker growing considerably faster than the market.
Answers to last quarter's watch list
What to watch into next quarter
Will the tariff line stay at ~$200M or move again? The in-period estimate rose $25M this quarter from $175M to $200M, and FX/rate-dependent language was layered into FY framing. If rates hold and Q4 FY2025 absorbs the back-half-weighted tariff load without further EPS pressure, the structural margin case strengthens further into FY2026 guidance.
MedSurg organic mix — Endoscopy at +7.0% reflected timing of infrastructure installations in communications OR; watch whether the elevated order book converts cleanly in Q4 FY2025 or signals a broader normalization in MedSurg organic to a high-single-digit run rate.
Orthopaedics ex-divested-Spinal durability — track whether the +12.5% reported / +11.4% organic Q3 FY2025 pace holds into Q4 FY2025 against a more difficult comp and whether Mako revision hip / new hinge revision knee system materially contribute. The competitive-disruption opportunity (peer's announced orthopaedic spinoff) is the upside case.
EPS high-end held at $13.60 for the second consecutive raise — management raised the low end by $0.10 but didn't move the ceiling. A Q4 FY2025 print that pushes Q4 organic above 9.5% with the operating margin commitment intact would likely force the high-end up; if not, FY EPS will likely settle near the midpoint.
Inari sales-force stabilization post-Q1 FY2026 — destocking is expected to fully burn through end of Q1 FY2026, after which procedural growth in the teens should translate cleanly to reported growth. Watch Q4 FY2025 commentary on sales-rep retention and any quantification of the Q1 FY2026 inflection.
Investor Day (November 13) — refreshed long-term financial goals including margin trajectory and updated tariff outlook for FY2026.
Sources
- Stryker Corporation, Q3 2025 Earnings Press Release (SEC EX-99.1): https://www.sec.gov/Archives/edgar/data/310764/000031076425000126/sykex991earningsq32025.htm
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.